Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Pommier

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
International Journal of Radiation Oncology, Biology, Physics|December 18, 2018
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)Loig Vaugier, Clément Palpacuer, Emmanuel Rio, et al.
European Urology Oncology|February 8, 2023
The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 StudyDavid Pasquier, Thomas Lacornerie, Stéphane Supiot, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 5, 2024
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trialLionel Perrier, Frédéric Balusson, Magali Morelle, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2022
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02)Séverine Racadot, Isabelle Thennevet, Yaelle Ouldbey, et al.
International Journal of Radiation Oncology, Biology, Physics|November 3, 2004
The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicityVéronique Beckendorf, Stéphane Guérif, Elisabeth Le Prisé, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 9, 2025
Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysisNajlaa Alyamani, Enrico Clementel, Paul Sargos, et al.
International Journal of Radiation Oncology, Biology, Physics|December 15, 2010
70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trialVéronique Beckendorf, Stéphane Guerif, Elisabeth Le Prisé, et al.
Critical Reviews in Oncology/Hematology|March 28, 2022
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology groupAriane Lapierre, Christophe Hennequin, Amandine Beneux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized TrialsLucia Kwak, Praful Ravi, John G Armstrong, et al.
British Journal of Cancer|January 6, 2024
Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASEClaire Gouriou, Claire Lemanski, Pascal Pommier, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
International Journal of Radiation Oncology, Biology, Physics|December 18, 2018
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)Loig Vaugier, Clément Palpacuer, Emmanuel Rio, et al.
European Urology Oncology|February 8, 2023
The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 StudyDavid Pasquier, Thomas Lacornerie, Stéphane Supiot, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 5, 2024
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trialLionel Perrier, Frédéric Balusson, Magali Morelle, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2022
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02)Séverine Racadot, Isabelle Thennevet, Yaelle Ouldbey, et al.
International Journal of Radiation Oncology, Biology, Physics|November 3, 2004
The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicityVéronique Beckendorf, Stéphane Guérif, Elisabeth Le Prisé, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 9, 2025
Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysisNajlaa Alyamani, Enrico Clementel, Paul Sargos, et al.
International Journal of Radiation Oncology, Biology, Physics|December 15, 2010
70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trialVéronique Beckendorf, Stéphane Guerif, Elisabeth Le Prisé, et al.
Critical Reviews in Oncology/Hematology|March 28, 2022
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology groupAriane Lapierre, Christophe Hennequin, Amandine Beneux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized TrialsLucia Kwak, Praful Ravi, John G Armstrong, et al.
British Journal of Cancer|January 6, 2024
Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASEClaire Gouriou, Claire Lemanski, Pascal Pommier, et al.
Pageof 12